araag2/HINT huggingface dataset:
Clinical trial NCT00337545 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: rad001
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens

          -  Measurable disease

          -  ECOG 0-2

        Exclusion Criteria:

          -  CNS disease

          -  Chemotherapy or radiotherapy < 4 weeks prior

          -  Active bleeding diathesis
Clinical trial NCT00538304 (phase 2, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost eye drops, placebo
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic glaucoma or ocular hypertension

          -  IOP controlled on Xalatan

        Exclusion Criteria:

          -  Uncontrolled medical conditions

          -  Known hypersensitivity to study medications
Clinical trial NCT00558558 (phase 2, status: terminated)
Conditions: anorexia, weight loss, cachexia
ICD codes: R63.0, F50.00, F50.01, F50.02, R63.4, R64
Drugs: haelan
SMILES: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
Reason stopped: 
    study terminated due to low recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Anorexia (defined as > 30mm on a visual analog scale [VAS] of 0 to 100mm)

          2. Weight loss (defined as weight loss > 5% within last 6 months)

          3. Normal cognition (per treating physician's opinion)

          4. Written informed consent

          5. Advanced solid tumor (defined as locally recurrent or metastatic disease)

          6. Patient must have perceived weight loss as a problem.

          7. Able to maintain oral food intake within one week prior to enrollment in this study.

        Exclusion Criteria:

          1. Evidence of ascites (per treating physician's opinion).

          2. Receiving supplementary tube feedings or parenteral nutrition

          3. Known mechanical obstruction of the alimentary tract, or intractable vomiting

          4. Add or change dose of the following medication within 2 weeks prior to this trial or
             during this trial: megestrol, corticosteroid, mirtazapine, metoclopramide and
             dronabinol, with the exception of pre-medication for chemotherapy (10-20 mg Decadron
             intavenous (IV) once and/or Reglan 10 mg IV x1 prior to chemotherapy).

          5. Allergic to soy.

          6. Positive pregnancy test for female patients of child-bearing potential. (Definition of
             child-bearing potential: not post-menopausal for past 12 months or nor surgically
             sterile)

          7. Female patients with child bearing potential, but refuse to practice accepted methods
             of contraception (acceptable forms of contraception include: continuous abstinence,
             Depo-Provera shot, tubal ligation, NuvaRing vaginal ring, Ortho Evra skin patch, oral
             contraceptive, IUD-Mirena, vasectomy, male condom, diaphragm).

          8. Weight less than 80 lb.

          9. Patient who could not tolerate oral intake of 2 Oz. of Haelan during the taste test.

         10. Diagnosed of breast cancer.
Clinical trial NCT00537823 (phase 2, status: terminated)
Conditions: colorectal cancer, metastases
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab, bevacizumab, leucovorin, oxaliplatin, fluorouracil
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    poor accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Synchronous or metachronous colorectal metastases

          -  Technically resectable liver metastases

               -  Four or fewer metastases

               -  No tumors in porta hepatis

               -  Resection of no more than 70% of liver needed

          -  Medically suitable candidate for major liver resection

          -  FDG-PET scan without metastatic disease outside the liver

        Exclusion Criteria:

          -  Near-obstructing or obstructing colon lesions in patients in whom combined resection
             is planned (as delay for preoperative chemotherapy would be medially impossible)

          -  Treatment with FOLFOX or cetuximab within 12 months

          -  Treatment with irinotecan within 12 months

          -  Abnormal liver function (ALT or AST > 5x ULN, bilirubin > 3x ULN)

          -  Body mass index >/= 35 kg/m² (as the risk for steatohepatitis is increased)

          -  Renal insufficiency (Cr > 2.5mg/dL)

          -  Interstitial lung disease (because cetuximab has been rarely associated with
             development of interstitial lung disease)

          -  ECOG performance score >/= 3

          -  Patients unable to give informed consent

          -  Pregnant patient (as cetuximab is a Class C drug)

          -  Peripheral neuropathy >/= grade II (as oxaliplatin causes neuropathy to worsen)
Clinical trial NCT00678964 (phase 2, status: unknown status)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib, vinorelbine and carboplatin
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytological proven NSCLC, stage lll b (with pleural effusion) or
             stage lV.

          -  Tumour is locally advanced and not suitable for surgery and radiotherapy is not
             indicated.

          -  Neither cytostatic nor immunological pre-treatment

          -  Age >70 years

          -  At least one measurable lesion (RECIST criteria) that was not previously irradiated

          -  ECOG Performance Status 0-1

          -  Life expectancy > 3 month

          -  Adequate bone marrow function: ANC > 1.5 x 109/L, Platelets > 100 x 109/L

          -  Adequate liver function: Total Bilirubin < 1.5 x ULN, GOT/GPT< 3 x ULN (existent liver
             metastases < 5 x ULN)

          -  Adequate renal function:creatinine clearance > 45 ml/min (calculated according to
             Cockroft-Gault)

          -  Fertile men must agree to use an effective method of birth control while participating
             in this study

          -  Signed written informed consent

        Exclusion Criteria:

          -  Uncontrolled metastasis in the CNS

          -  Acute, heavy uncontrolled infection

          -  Any other serious concomitant disease or medical condition, which could interfere with
             participating in this study

          -  Severe hypersensitivity to Erlotinib or any other component

          -  Hypersensitivity to Carboplatin and/or other platinum compounds

          -  Hypersensitivity to Vinorelbin or other Vinca-alkaloids

          -  Patients with a history of other active malignancy in the past 5 years (with the
             exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local
             prostate carcinoma that was surgically treated successfully) are excluded.

          -  Participation in another clinical trial with any investigational drug at the same time
             or within 30 days prior to registration

          -  Psychological, familial, social or geographical situations limiting the compliance
             with the study requirements
Clinical trial NCT00517049 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pro95780, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age ≥ 18 years

          -  Diagnosis of follicular, CD20-positive B-cell NHL

          -  Progression of disease after an objective response or stable disease lasting > 6
             months following completion of the most recent rituximab-containing regimen

          -  Measurable disease

          -  Life expectancy of > 3 months

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma (according to the WHO classification) or histologic
             transformation from follicular lymphoma to aggressive lymphoma

          -  Prior radiotherapy to a lesion(s) that will be used to assess response unless that
             lesion(s) shows clear evidence of lymphoma progression at baseline

          -  Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1 or
             radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle
             1, Day 1

          -  Concurrent systemic corticosteroid therapy

          -  Other invasive malignancies within 3 years prior to first study drug administration
             except for adequately treated basal or squamous cell skin cancer, in situ carcinoma of
             the cervix, in situ breast cancer, in situ prostate cancer, limited-stage bladder
             cancer, or other cancers from which the patient has been disease-free for at least 3
             years.

          -  History or evidence on physical examination of central nervous system (CNS) disease

          -  Prior treatment with agonistic DR4 or DR5 antibodies or Apo2L/TRAIL
Clinical trial NCT01459926 (phase 2, status: completed)
Conditions: opioid induced constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: td-1211, td-1211, td-1211, placebo
SMILES: NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of constipation with onset after initiation of opioid therapy

          -  Self-reported OIC of approximately 3 spontaneous bowel movements (SBMs) per week or
             less for each week over at least the previous two week period

          -  Have used chronic opioids with a total daily dose ≥30 mg of morphine equivalent units
             (MEU, Appendix 7) for the 12 weeks preceding the Screening Visit. Subjects should have
             used a stable daily regimen of opioids for at least the 2 weeks preceding the
             Screening Visit

          -  Willing to stop all laxatives and other bowel regimens with the exception of
             bisacodyl/enema treatment allowed per protocol throughout the OIC confirmation,
             treatment, and follow-up periods

        Exclusion Criteria:

          -  Have participated in a clinical trial of an investigational drug or medical device
             within 30 days prior to Screening

          -  Have any condition that may affect drug absorption, (e.g., previous GI surgery)

          -  Any other condition which, in the opinion of the investigator, could confound or
             interfere with evaluation of safety or tolerability of the investigational drug, or
             prevent compliance with the study protocol
Clinical trial NCT00510406 (phase 2, status: completed)
Conditions: lower urinary tract symptoms, prostatic hyperplasia
ICD codes: N40.2, N40.3, N40.0, N40.1, N40.0, N40.1
Drugs: tamsulosin hydrochloride, solifenacin succinate, placebo
SMILES: CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O, O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  male patients with LUTS associated with BPH diagnosed > 3 months

          -  IPSS score > 13

          -  voiding and storage symptoms

          -  maximum flow rate of > 4 mL/s and < 15 mL/s

        Exclusion Criteria:

          -  post void residual volume > 200 mL

          -  symptomatic urinary tract infection
Clinical trial NCT00382694 (phase 2, status: unknown status)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Multiple myeloma, stage I-III, previously untreated, and eligible for induction
             therapy followed by high dose treatment supported by autologous stem cell
             transplantation.

        Exclusion Criteria:

          -  Severe uncontrolled clinical or microbiological evidence of infection at the time of
             enrolment.

          -  Other active malignancy.

          -  Severe coincident heart or lung disease including uncontrolled hypertension, unstable
             angina, congestive heart failure, coronary angioplasty within six months, myocardial
             infarction within the last six months, or uncontrolled cardiac arrhythmia.

          -  Other severe illness including poorly controlled diabetes.

          -  Haemolytic anaemia (Coombs positive without evidence of haemolysis is accepted).

          -  Idiopathic thrombocytopenic purpura.

          -  Terminal illness.

          -  Allogenic transplantation planned within 6 months.

          -  Chemotherapy before inclusion.

          -  Pregnancy or breast-feeding, or inadequate contraceptive precautions.

          -  Psychiatric disease, abuse of alcohol or narcotics, or any other disorder that might
             compromise the patients ability to give informed consent.
Clinical trial NCT00317395 (phase 2, status: completed)
Conditions: coronary disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: otamixaban (xrp0673), unfractionated heparin, eptifibatide
SMILES: COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ischemic discomfort at rest ≥ 10 minutes within 24 hours of randomization

          -  Electrocardiogram (ECG) criteria for non-ST elevation ACS or cardiac enzyme elevation
             (> upper limit of normal [ULN])

          -  No ST elevation Myocardial Infarction (STEMI)

          -  Planned coronary angiography followed when indicated by a Percutaneous Coronary
             Intervention (PCI) on Day 1 to Day 3

        Exclusion Criteria:

          -  Inability to undergo coronary angiography or PCI by Day 3

          -  Prior PCI within 30 days

          -  Acute STEMI

          -  Cardiogenic shock

          -  Anticoagulant treatment for > 24 hours prior to randomization

          -  Prior treatment with fondaparinux since ACS onset

          -  Requirement for oral anticoagulant (OAC) prior to Day 30

          -  Creatinine clearance < 30 ml/min
Clinical trial NCT00733668 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine fumarate (seroquel)
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Inform consent

          -  Male and female, age between 18 and 65 years.

          -  Naïve to any atypical antipsychotic

          -  A diagnosis of major depressive disorder

        Exclusion Criteria:

          -  No use of fluvoxamine

          -  Patients with a history of bipolar I or II disorder

          -  Diagnosis of psychotic major depression disorder
Clinical trial NCT00580112 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: dexamethasone, trabectedin
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with histologically proven diagnosis of progressive metastatic breast
             cancer

          -  Participants with measurable disease as per the Response Evaluation Criteria In Solid
             Tumors (RECIST) guidelines

          -  Participants with bone metastases currently receiving bisphosphonates for palliation
             will be eligible if other sites of measurable disease are present

          -  Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0
             or 1 and adequately recovered from the acute toxicity of any prior treatment

          -  Participants with serum creatinine less than or equal to 1.5 milligram per deciliter
             (mg/dl) or creatinine clearance greater than or equal to 30 milliliter per minute
             (ml/min)

        Exclusion Criteria:

          -  Participants with previous exposure to trabectedin

          -  Participants with more than 3 previous chemotherapy regimens for metastatic disease
             and known hypersensitivity to components of trabectedin intravenous formulation or
             dexamethasone

          -  Pregnant or lactating women or any women of childbearing potential who is not
             employing adequate contraception

          -  Completion of previous therapy : Less than 2 weeks from radiation therapy or last dose
             of hormonal therapy, less than 3 weeks from previous biological therapy or
             chemotherapy

          -  Participants with known leptomeningeal disease and other serious illnesses like
             congestive heart failure or angina pectoris; myocardial infarction within 1 year
             before enrolment; uncontrolled arterial hypertension or arrhythmias or active
             infection or psychiatric disorder or active viral hepatitis
Clinical trial NCT00667862 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: panobinostat
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO
Eligibility criteria:

        Inclusion criteria:

          -  Confirmed diagnosis of adenocarcinoma of the prostate

          -  Patients with metastatic hormone refractory prostate cancer

          -  Patients that have had at least one, but not more than two prior cytotoxic treatments
             for prostate cancer

          -  Evidence of disease progression by at least one of the following

               1. two or more lesions on bone scan

               2. progressive measurable disease

               3. two documented increases in PSA

          -  Willing to use contraception throughout the study and for 12 weeks after study
             completion

        Exclusion criteria:

          -  History or clinical signs of CNS disease

          -  History of other cancers not curatively treated with no evidence of disease for more
             than 5 years

          -  Prior radiotherapy within 3 weeks of starting study treatment

          -  Prior radiopharmaceuticals (strontium, samarium)

          -  Impaired cardiac function

          -  Heart disease

          -  Liver or renal disease with impaired function

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00448760 (phase 2, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: docetaxel, floxuridine, leucovorin, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of adenocarcinoma of the esophagus meeting the following criteria:

               -  Stage II or III disease

               -  Resectable disease

               -  Previously untreated disease

          -  No stage I (mucosal only) or stage IV (metastatic) disease

        PATIENT CHARACTERISTICS:

          -  WBC > 3,000/mm^3

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count > 100,000/mm^3

          -  Creatinine ≤ 2.0 mg/dL

          -  Bilirubin < 2 times normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Must have central venous access

          -  No other malignancy within the past 5 years

          -  No concurrent medical or psychiatric problem that would preclude study treatment

          -  No contraindications to paclitaxel

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy to the esophagus

          -  No oral cryotherapy (e.g., ice chips) on day 1 of each course